Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Thursday 5 November →